Dako Receives FDA Approval For Fast, Accurate, Nontoxic FISH Assay For Cancer Diagnostics

Dako, an Agilent Technologies Company, has introduced IQISH technology in the United States. The technology will reduce the turnaround time for cancer evaluation from two days to three and a half hours. This will ease the waiting time and associated anxiety for the patient and allow physicians to more quickly initiate targeted cancer treatments. HER2 IQFISH pharmDx, a fluorescence in situ hybridization (FISH) assay, is the first product approved by the U.S. Food and Drug Administration that uses the Dako IQISH technology, which is based on Dako's fast IQISH hybridization buffer chemistry...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Medical Devices / Diagnostics Source Type: news